Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of GI-101A plus SL-T10 in metastatic castration-resistant prostate cancer
KCT0008799Phase 2Not yet recruiting
- Sponsor
- GI Innovation
- Start
- Oct 2023
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GI-101A and SL-T10 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by GI Innovation. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
GI-101ASL-T10
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on KCT0008799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008799.